Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensity-modulated radiation therapy and concurrent chemotherapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Zhang W, Chen Y, Chen L, Guo R, Zhou G, Tang L, et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore) 2015; 94: e845. 10.1097/md.0000000000000845ZhangWChenYChenLGuoRZhouGTangLThe clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 casesMedicine (Baltimore)201594e84510.1097/md.0000000000000845Open DOISearch in Google Scholar
Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr Virus DNA to screen for nasopharyngeal cancer. N Engl J Med 2017; 377: 513-22. 10.1056/NEJMoa1701717ChanKCAWooJKSKingAZeeBCYLamWKJChanSLAnalysis of plasma Epstein-Barr Virus DNA to screen for nasopharyngeal cancerN Engl J Med20173775132210.1056/NEJMoa170171728792880Open DOISearch in Google Scholar
Peng H, Guo R, Chen L, Zhang Y, Li WF, Mao YP, et al. Prognostic impact of plasma Epstein-Barr Virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. Sci Rep 2016; 6: 22000. 10.1038/srep22000PengHGuoRChenLZhangYLiWFMaoYPPrognostic impact of plasma Epstein-Barr Virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapySci Rep201662200010.1038/srep22000477042026924234Open DOISearch in Google Scholar
Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-9.ChanATLoYMZeeBChanLYMaBBLeungSFPlasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinomaJ Natl Cancer Inst2002941614910.1093/jnci/94.21.161412419787Search in Google Scholar
Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24: 5414-8. 10.1200/jco.2006.07.7982LeungSFZeeBMaBBHuiEPMoFLaiMPlasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinomaJ Clin Oncol2006245414810.1200/jco.2006.07.7982Open DOISearch in Google Scholar
Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. Int J Radiat Oncol Biol Phys 2015; 91: 325-36. 10.1016/j.ijrobp.2014.10.005TangLQLiCFChenQYZhangLLaiXPHeYHigh-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort studyInt J Radiat Oncol Biol Phys2015913253610.1016/j.ijrobp.2014.10.00525482300Open DOISearch in Google Scholar
Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-70. 10.1056/NEJMoa032260LinJCWangWYChenKYWeiYHLiangWMJanJSQuantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinomaN Engl J Med200435024617010.1056/NEJMoa03226015190138Open DOISearch in Google Scholar
Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 130-7. 10.1016/j.ijrobp.2006.07.012TwuCWWangWYLiangWMJanJSJiangRSChaoJComparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys200767130710.1016/j.ijrobp.2006.07.01216979842Open DOISearch in Google Scholar
Alfieri S, lacovelli NA, Marceglia S, Lasorsa I, Resteghini C, Taverna F, et al. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. Oncotarget 2017; 8: 47780-9. 10.18632/oncotarget.17822AlfieriSlacovelliNAMarcegliaSLasorsaIResteghiniCTavernaFCirculating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic areaOncotarget2017847780910.18632/oncotarget.17822556460428562354Open DOISearch in Google Scholar
Wei W, Huang Z, Li S, Chen H, Zhang G, Li S, et al. Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area. Oncol Res Treat 2014; 37: 88-95. 10.1159/000360178WeiWHuangZLiSChenHZhangGLiSPretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic areaOncol Res Treat201437889510.1159/00036017824685911Open DOISearch in Google Scholar
Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS, Chao JY, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010; 16: 1016-24. 10.1158/1078-0432.ccr-09-2796WangWYTwuCWChenHHJanJSJiangRSChaoJYPlasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinomaClin Cancer Res20101610162410.1158/1078-0432.ccr-09-279620103659Open DOISearch in Google Scholar
Prayongrat A, Chakkabat C, Kannarunimit D, Hansasuta P, Lertbutsayanukul C. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. J Radiat Res 2017; 58: 509-16. 10.1093/jrr/rrw128PrayongratAChakkabatCKannarunimitDHansasutaPLertbutsayanukulC.Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinomaJ Radiat Res2017585091610.1093/jrr/rrw128557007728204596Open DOISearch in Google Scholar
Hou X, Zhao C, Guo Y, Han F, Lu LX, Wu SX, et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 128-33. 10.1016/j.clon.2010.09.001HouXZhaoCGuoYHanFLuLXWuSXDifferent clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapyClin Oncol (R Coll Radiol)2011231283310.1016/j.clon.2010.09.00120943358Open DOISearch in Google Scholar
Lee VH, Kwong DL, Leung TW, Choi CW, Lai V, Ng L, et al. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. Oncotarget 2017; 8: 5292-308. 10.18632/oncotarget.14137LeeVHKwongDLLeungTWChoiCWLaiVNgLPrognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinomaOncotarget20178529230810.18632/oncotarget.14137535490928029657Open DOISearch in Google Scholar
Twu CW, Wang WY, Chen CC, Liang KL, Jiang RS, Wu CT, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys 2014; 89: 21-9. 10.1016/j.ijrobp.2014.01.052TwuCWWangWYChenCCLiangKLJiangRSWuCTMetronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acidInt J Radiat Oncol Biol Phys20148921910.1016/j.ijrobp.2014.01.05224725686Open DOISearch in Google Scholar
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-7. 10.1200/jco.1998.16.4.1310Al-SarrafMLeBlancMGiriPGFuKKCooperJVuongTChemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099J Clin Oncol1998161310710.1200/jco.1998.16.4.1310Open DOISearch in Google Scholar
Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage Ill and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23: 6730-8. 10.1200/jco.2005.16.790WeeJTanEHTaiBCWongHBLeongSSTanTRandomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage Ill and IV nasopharyngeal cancer of the endemic varietyJ Clin Oncol2005236730810.1200/jco.2005.16.790Open DOISearch in Google Scholar
Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs. radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010; 102: 1188-98. 10.1093/jnci/djq258LeeAWTungSYChuaDTNganRKChappellRTungRRandomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs. radiotherapy alone for regionally advanced nasopharyngeal carcinomaJ Natl Cancer Inst201010211889810.1093/jnci/djq25820634482Open DOISearch in Google Scholar
Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer 2017; 75: 150-8. 10.1016/j.ejca.2017.01.002ChenLHuCSChenXZHuGQChengZBSunYAdjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trialEur J Cancer201775150810.1016/j.ejca.2017.01.00228235726Open DOISearch in Google Scholar
Lo YM, Leung SF, Chan LY, Chan AT, Lo KW, Johnson PJ, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000; 60: 2351-5.LoYMLeungSFChanLYChanATLoKWJohnsonPJKinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinomaCancer Res20006023515Search in Google Scholar
Leung SF, Chan KC, Ma BB, Hui EP, Mo F, Chow KC, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25: 1204-8. 10.1093/annonc/mdu117LeungSFChanKCMaBBHuiEPMoFChowKCPlasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinomaAnn Oncol2014251204810.1093/annonc/mdu11724638904Open DOISearch in Google Scholar
Songthong AP, Kannarunimit D, Chakkabat C, Lertbutsayanukul C. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. Radiat Oncol 2015; 10: 166. 10.1186/s13014-015-0472-ySongthongAPKannarunimitDChakkabatCLertbutsayanukulC.A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse eventsRadiat Oncol20151016610.1186/s13014-015-0472-y455436926253488Open DOISearch in Google Scholar
Liu TB, Zheng ZH, Pan J, Pan LL, Chen LH. Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis. Clin Invest Med 2017; 40: E1-e12.LiuTBZhengZHPanJPanLLChenLH.Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysisClin Invest Med201740E1e1210.25011/cim.v40i1.2804928218577Search in Google Scholar
Lertbutsayanukul C, Prayongrat A, Kannarunimit D, Chakkabat C, Netsawang B, Kitpanit S. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. Strahlenther Onkol 2018. 10.1007/s00066-017-1251-5. [Epub ahead of print]LertbutsayanukulCPrayongratAKannarunimitDChakkabatCNetsawangBKitpanitS.A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinomaStrahlenther Onkol201810.1007/s00066-017-1251-5[Epub ahead of print]29302704Open DOISearch in Google Scholar
Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys 2012; 82: 327-33. 10.1016/j.ijrobp.2010.09.011SuSFHanFZhaoCChenCYXiaoWWLiJXLong-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy aloneInt J Radiat Oncol Biol Phys2012823273310.1016/j.ijrobp.2010.09.01121035959Open DOISearch in Google Scholar
Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2009; 74: 1070-6. 10.1016/j.ijrobp.2008.09.008XiaoWWHanFLuTXChenCYHuangYZhaoC.Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys2009741070610.1016/j.ijrobp.2008.09.00819231110Open DOISearch in Google Scholar
